Tag Archives: finance

Hot Investor Mandate: Early-Stage Focused VC Firm Invests in Pre-Seed to Series A Healthcare Companies With AI-Driven Technologies

12 Nov

This venture capital firm with offices in the US is exclusively focused on the AI transformation of healthcare, operating through a physician-centric model that leverages a broad network of medical professionals actively involved in both the investment process and the development of AI solutions, particularly in medical imaging. 

The firm invests at the pre-Seed, Seed, and Series A stages, with typical check sizes ranging from $1 million to $2 million. While most investments have been made in U.S.-based companies, the firm remains open to international opportunities, including those in Europe and Asia. 

Investment focus is tightly concentrated on disruptive AI-driven technologies in the medical imaging market. The firm does not invest in traditional therapeutics or medical devices, and is currently not considering opportunities outside of AI-centric digital health technologies related to imaging. It is open to investing in companies as early as the pre-prototype stage, provided they are aligned with the firm’s strategic thesis. 

The firm seeks to partner with highly driven management teams who possess deep domain expertise across imaging, artificial intelligence, and medical software. While the firm typically co-invests, it maintains an active, hands-on approach, especially through the support of its physician investor network, which helps accelerate product development and clinical relevance. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Family Office-Backed Life Sciences Fund Invests Across Therapeutics, Diagnostics, and Digital Health Globally

12 Nov

This life sciences-focused investment firm backed by a prominent family office is actively investing in life science and healthcare companies across the globe, with a focus on those that are based near their headquarters. 

The firm invests in early-stage healthcare companies, with interest in therapeutics, diagnostics, and digital health. It is agnostic to technology type and therapeutic indication, but prefers opportunities with robust pre-clinical data. The firm is open to both pre-clinical and clinical-stage projects, though it does not invest in medical device companies at this time. 

The firm is focused on supporting innovative technologies and is open to partnering with both first-time and experienced founding teams. It is flexible in its role, willing to act as either a lead investor or a co-investor, depending on the structure and needs of the financing round.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Evergreen Fund Actively Seeking Therapeutics and Medical Device Opportunities, Investing Up to $10M in the US and Beyond

12 Nov

This corporate strategic evergreen fund based in the US has invested in over 50 life sciences companies and considers both public and private opportunities in the United States and internationally. The firm is a flexible investor, with initial allocations typically ranging from $1 million to $10 million, depending on the developmental stage of the company. 

The firm invests in therapeutics and medical devices, with the latter limited to implantable products requiring PMA submission. It invests exclusively in companies with clinical-stage assets, and is indication-agnostic, open to innovation across all areas of medicine. 

This investor adopts a flexible approach to management teams, and is willing to take a more hands-on role in cases where founding teams have limited internal resources. A high level of transparency is required from portfolio companies, and the firm actively supports strategic planning around value-driving clinical studies that can meaningfully advance the company’s trajectory. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Europe-Based VC Invests Across All Life Science Sectors, With A Focus on Those Based in US and Europe

12 Nov

A Europe-based venture capital firm invests across two primary verticals: healthcare innovation and sustainability. The firm typically invests at the seed stage, with initial check sizes ranging from €1 million to €5 million. Its geographic deployment is relatively balanced, with approximately half of investments made in Europe and the other half in the United States. The firm shows particular interest in U.S.-based companies founded by European entrepreneurs. 

The firm invests across therapeutics, diagnostics, medical devices, and digital health, taking an agnostic approach within these sectors. It does not enforce strict criteria regarding the composition or background of founding teams. 

Open to both leading and co-investing, the firm places strong emphasis on the mission and purpose behind each company, placing value on teams with a compelling “why” that drives their approach to solving pressing problems in healthcare. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Beyond Borders: How to Prepare for Partnering Success at RESI London in the “Winter” 

4 Nov

By Greg Mannix, VP, EMEA Business Development, LSN

When was the last time you spoke directly with an investor? Or better yet how often do you have the chance to meet with multiple qualified investors in a single day? 

In today’s challenging investment climate, life science startups can’t afford to slow down their fundraising efforts. Capital is still out there, but it requires thinking beyond borders. 

To thrive in this “winter,” fundraising CEOs must: 

  • Step outside their regional ecosystems 
  • Build global visibility 
  • Connect directly with investors, in-licensors, and strategic partners who are still actively deploying capital 

That is exactly what RESI London 2025 is designed to help you do. 

Why Partnering Conferences Matter 

Partnering conferences, like RESI, give startups a fast, efficient way to meet investors who are aligned with their technology, stage, and strategy. Instead of spending months chasing introductions, companies can meet dozens of potential partners across two or three days. These concentrated interactions save time, reduce travel costs, and dramatically increase fundraising success rates. 

How to Prepare for a Partnering Conference 

Preparation determines success. Before meetings begin, make sure your company profile, pitch deck, and meeting strategy are ready. 

Join Life Science Nation’s free Partnering Tutorial Webinar on Monday, November 10 at 10 AM Eastern to learn how to navigate the RESI Partnering Platform, refine your outreach, and get ready to meet investors. 

Sign Up Free Webinar

RESI’s Unique Approach to Partnering 

Unlike most conferences, which offer only basic scheduling tools, the RESI Partnering Platform is built specifically for early-stage life sciences. It features a curated database of investor profiles gathered through direct interviews. Startups can filter investors by type, indication, and development stage to find their most relevant matches. This data-driven approach makes your meetings more targeted and impactful. 

RESI Survival Guide 

To help fundraising executives make the most of RESI, LSN developed the RESI Survival Guide, outlining five essential steps to partnering success. It covers how to identify the right investors, structure your day, and follow up effectively after the event. 

Ways to Partner: Standard vs. Premier Access 

Premier Access attendees enjoy additional benefits, including early access to investor profiles, enhanced visibility, and dedicated support from the LSN team. Whether you choose Standard or Premier, every investor profile on the RESI platform is verified and interviewed to ensure a high-quality partnering experience. 

Register for RESI London Appy to Pitch at RESI London

Tags: , , , , ,

Hot Investor Mandate: Europe-Based VC Firm Invests in Early-Stage Companies in Tech-Enabled Life Science and Healthcare Companies

4 Nov

 
This growth-focused investment firm is headquartered in Europe, and was founded by entrepreneurs who previously built and exited a unicorn multinational company. With a renewed mission to drive innovation and growth, the firm targets both early-stage life science ventures and established professional service providers. 

In the early-stage segment, the firm typically invests up to €500K in Series A rounds and makes smaller allocations at the Seed stage. The investment strategy centers on innovative, tech-enabled, and service-oriented companies within the life sciences and healthcare sectors. While the firm is open to early-stage opportunities, it prefers companies with a proven business model and a clear path to scale. 

The firm is eager to partner with strong management teams developing solutions that address unmet needs with a compelling value proposition. Most investments are made as part of a syndicate with institutional venture capital firms, and the firm contributes beyond capital by offering deep sector expertise, an extensive network, and a strong entrepreneurial track record. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Western Europe-Based Firm Invests Up to $10M in Life Sciences Including Drug Discovery and Enabling Technologies

4 Nov

This Western Europe-based investment firm has been active for over two decades and manages multi-billion in assets under management. The firm takes a sector-agnostic approach, investing across a broad spectrum including enterprise software, fintech, consumer technologies, deeptech, and life sciences. 

Typical equity investments range from $1 million to $10 million, and the firm expects to make several new investments annually. While companies must maintain a local operational presence in the firm’s home country, they may also have international footprints. 

In the life sciences and biotech space, the firm adopts a wide-angle lens, looking for companies developing drug discovery platforms, synthetic biology innovations, and enabling research technologies.  

The firm is open to investing in pre-revenue companies, and is supportive of both emerging and experienced founding teams. It frequently invests at the early growth stage, often in syndicate with other institutional investors.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

← Older Entries
Newer Entries →